Third-Party Tested- Fast U.S. Shipping- Secure Checkout

RETATRUTIDE

$91.00

⚠ For laboratory research use only. Not for human consumption.

CAS NO: 2381089-83-2
Molecular Formula: C221H342N46O68
Molecular Weight: 4731.3476
Appearance: white powder
Lyophilized powder for optimal stability
Storage: 2-8°
Purity: ≥99%

In Stock

-
+
Add to Wishlist
Add to Wishlist

Description

⚠ For laboratory research use only. Not for human consumption.

CAS NO: 2381089-83-2

Molecular Formula: C221H342N46O68

Molecular Weight: 4731.3476

Appearance: white powder

Lyophilized powder for optimal stability

Storage: 2-8°

Purity: ≥99%

Elite Wellness Peptide presents pharmaceutical-grade Retatrutide 12mg, a cutting-edge GLP-1/GIP/Glucagon triple-receptor agonist designed for advanced metabolic research. This next-generation peptide offers unprecedented opportunities for studying obesity mechanisms, glucose homeostasis, and fat metabolism in controlled laboratory settings.

Elite Wellness Peptide offers research-grade Retatrutide 12mg, a cutting-edge triple-receptor agonist for advanced metabolic studies. This novel peptide enables investigation of:

Weight regulation mechanisms

Glucose homeostasis

Lipid metabolism

Cardiometabolic protection


SCIENTIFIC OVERVIEW OF RETATRUTIDE

Retatrutide (LY3437943) represents a breakthrough in metabolic peptide research, combining three potent mechanisms of action:

GLP-1 Receptor Agonism – Enhances insulin secretion and satiety

GIP Receptor Modulation – Improves nutrient partitioning

Glucagon Receptor Activity – Increases energy expenditure


KEY RESEARCH APPLICATIONS


Obesity & Weight Regulation Studies

Demonstrated 2% body weight reductionin primate models (vs 17.5% with semaglutide)

Targets visceral adipose tissuewith 38% greater efficacy than dual agonists

Glucose Metabolism Research

Lowers fasting glucose by 1-3.8 mmol/Lin diabetic models

Improves HOMA-IR scores by 62%vs controls


Lipid Metabolism Investigations

Reduces liver fat content by 43-51%in NAFLD models

Lowers triglycerides by 29%more than GLP-1 mono-agonists


Cardiometabolic Protection Studies

Shows 22% greater CVD risk reductionvs comparators

Preserves lean mass during weight loss (only 3% lossvs 14.1% with diet alone)

 


WHY RETATRUTIDE OUTPERFORMS EXISTING COMPOUNDS

COMPARATIVE EFFICACY DATA

 

Parameter Retatrutide Tirzepatide Semaglutide
Weight Loss 24.2% 17.5% 14.9%
Glucose Control -2.8 mmol/L -2.1 mmol/L -1.7 mmol/L
Lean Mass Ret. 91.7% 88.2% 85.9%
Liver Fat Red. 51% 39% 33%

 


EXPERIMENTAL PREPARATION

For accurate research application:

  1. Reconstitutewith appropriate volume of bacteriostatic water
  2. Inject BAC water slowly down the inside wall of the vial, rather than directly onto the powder.
  3. Gently swirluntil fully dissolved (do not vortex)
  4. Administerimmediately or store at 4°C protected from light
  5. Reconstituted: Stable 30 days at 4°C

IMPORTANT: This product is intended strictly for laboratory research purposes only. NOT for human or animal consumption. NOT for medical or diagnostic use. These products have not undergone evaluation by the U.S. Food and Drug Administration. By purchasing, you confirm compliance with all applicable regulations.

 

Reviews

There are no reviews yet.

Be the first to review “RETATRUTIDE”

Your email address will not be published. Required fields are marked *